Breast Cancer: Ovarian Suppression Benefits High-Risk Premenopausal Patients

Recent randomized clinical trials support the advantages of ovarian function suppression added to endocrine therapy compared with standard adjuvant endocrine therapy alone in higher-risk premenopausal women with hormone-sensitive breast cancer. The findings were included in the American Society of Clinical Oncology's most recent clinical practice guideline update on the topic.

 MedPage Today